Pacira Pharms Inc patent expiration

1. Depocyt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5455044 PACIRA PHARMS INC Method for treating neurological disorders
May, 2013

(11 years ago)

US5723147 PACIRA PHARMS INC Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
Mar, 2015

(9 years ago)




Drugs and Companies using CYTARABINE ingredient

Market Authorisation Date: 01 April, 1999

Treatment: Intrathecal treatment of lymphomatous meningitis

Dosage: INJECTABLE, LIPOSOMAL

More Information on Dosage

DEPOCYT family patents

Family Patents

2. Depodur patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5723147 PACIRA PHARMS INC Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
Mar, 2015

(9 years ago)

US5931809 PACIRA PHARMS INC Epidural administration of therapeutic compounds with sustained rate of release
Jul, 2015

(9 years ago)

US5807572 PACIRA PHARMS INC Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
Sep, 2015

(8 years ago)

US5997899 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Sep, 2016

(7 years ago)

US6241999 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Sep, 2016

(7 years ago)

US6193998 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Sep, 2016

(7 years ago)

US6171613 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Oct, 2016

(7 years ago)

US5962016 PACIRA PHARMS INC Multivesicular liposomes utilizing neutral lipids to modify in vivo release
Jan, 2017

(7 years ago)

US5891467 PACIRA PHARMS INC Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
Jan, 2017

(7 years ago)




Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 18 May, 2004

Treatment: Single-dose administration by the epidural route, at the lumbar level, for the treatment of pain following major surgery

Dosage: INJECTABLE, LIPOSOMAL

More Information on Dosage

DEPODUR family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Exparel patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6132766 PACIRA PHARMS INC Multivesicular liposomes with controlled release of encapsulated biologically active substances
Nov, 2013

(10 years ago)

US8182835 PACIRA PHARMS INC Sustained-release liposomal anesthetic compositions
Sep, 2018

(5 years ago)

US9205052 PACIRA PHARMS INC Sustained-release liposomal anesthetic compositions
Sep, 2018

(5 years ago)

US8834921 PACIRA PHARMS INC Sustained-release liposomal anesthetic compositions
Sep, 2018

(5 years ago)

US9585838 PACIRA PHARMS INC Production of multivesicular liposomes
Dec, 2021

(2 years ago)

US11179336 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11426348 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11452691 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11033495 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11357727 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11925706 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11311486 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11278494 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11304904 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11819574 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11819575 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(16 years from now)

US11931459 PACIRA PHARMS INC Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
Mar, 2042

(17 years from now)

US11918565 PACIRA PHARMS INC Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
Feb, 2043

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 28, 2014
New Indication(I-771) Apr 06, 2021
New Patient Population(NPP) Mar 22, 2024
New Indication(I-929) Nov 09, 2026

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 28 October, 2011

Treatment: Single dose administration into the surgical site to produce postsurgical analgesia; Single-dose infiltration into the surgical site to produce postsurgical analgesia.; Method of treating pain, for ex...

Dosage: INJECTABLE, LIPOSOMAL

How can I launch a generic of EXPAREL before it's drug patent expiration?
More Information on Dosage

EXPAREL family patents

Family Patents

4. Zilretta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555048 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(7 years from now)

US8828440 PACIRA PHARMS INC Corticosteroids for the treatment of joint pain
Aug, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 06, 2020

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 06 October, 2017

Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ZILRETTA family patents

Family Patents